Cumberland Pharmaceuticals Inc.
CPIX
Rank in Stocks
#20678
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical... Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.
Share Price
$5.37
Last synced: 2026-11-09
Market Cap
$80.46M
Change (1 day)
2.87%
Change (1 year)
168.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cumberland Pharmaceuticals Inc. (CPIX)
Category
Healthcare
EPS for Cumberland Pharmaceuticals Inc. (CPIX)
EPS as of June 2026 TTM: $-0.71
According to Cumberland Pharmaceuticals Inc.'s latest financial reports, its current EPS (TTM) is $-0.71. At the end of 2025 the company had an EPS of $-0.19, an increase over its 2024 EPS of $-0.46.
EPS history for Cumberland Pharmaceuticals Inc. from 2005 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.71 | 273.68% |
| 2025 | $-0.19 | -58.70% |
| 2024 | $-0.46 | 4.55% |
| 2023 | $-0.44 | 15.79% |
| 2022 | $-0.38 | 58.33% |
| 2021 | $-0.24 | 9.09% |
| 2020 | $-0.22 | -4.35% |
| 2019 | $-0.23 | -48.89% |
| 2018 | $-0.45 | -10.00% |
| 2017 | $-0.50 | 733.33% |
| 2016 | $-0.06 | -250.00% |
| 2015 | $0.04 | -71.43% |
| 2014 | $0.14 | -227.27% |
| 2013 | $-0.11 | -136.67% |
| 2012 | $0.30 | 7.14% |
| 2011 | $0.28 | 133.33% |
| 2010 | $0.12 | -45.45% |
| 2009 | $0.22 | -53.19% |
| 2008 | $0.47 | 17.50% |
| 2007 | $0.40 | -11.11% |
| 2006 | $0.45 | 114.29% |
| 2005 | $0.21 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -1,015.69% |
DE
|
|
| $6.08 | -956.00% |
DE
|
|
| $1.55 | -318.39% |
JP
|
|
| $3.66 | -615.49% |
CH
|
|
| $0.45 | -163.38% |
IL
|
Questions about Cumberland Pharmaceuticals Inc.'s earnings per share (EPS)
What is Cumberland Pharmaceuticals Inc.'s earnings per share (EPS)?
Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) over the last twelve months is $-0.71, as of Jun 2026.
What was Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) in 2025?
In 2025, Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) was $-0.19, compared with $-0.46 in 2024.
How has Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) was highest in 2025 ($-0.19) and lowest in 2024 ($-0.46).
How does Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) compare with similar companies?
Cumberland Pharmaceuticals Inc.'s earnings per share (EPS) ($-0.71) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.